Abstract 1854P
Background
Impaired perception of time has been associated with many psychiatric and neurological diseases. Time perception has been studied with different validated scales in the literature. However, the length of these scales limits its feasibility. The aim of our study was to evaluate the relationship of “1 minute” time perception with depression and anxiety in cancer patients receiving chemotherapy.
Methods
The cancer patients receiving active systemic therapy were included in the study. Time perception assessment was performed by testing how they perceived the 1-minute period. The patients were asked to guess the length of 1 minute by using a chronometer. Time perception duration (TPD) were recorded. The median 39 seconds was used to categorize patients as fast and slow time perception. Depression and anxiety were evaluated using the Hospital Anxiety and Depression Scale (HADS).
Results
In the study; 242 patients with a median age of 61 (33-88 years) were evaluated. In the TPD evaluation, the median estimation time was 39s (7-135sec) and 50.4% was found to be rapid time perception (<39sec). Anxiety and depression scores were recorded as high in 12% of the patients. There was no significant correlation between TPD and anxiety (r=0.027, p=0.68) and depression scores (r= 0.017, p= 0.79). TPD was similar between the groups with high and normal anxiety scores (39 vs 39 sec, p= 0.90) and those with short perception patients were similar in both groups (51.7% vs 50.2%, p=0.51). TPD was shorter in those with high depression scores (34 vs 40s, p= 0.37). Those with rapid TDP were more common in these patients, but this did not reach statistical significance (58.6% vs 49.3%, p= 0.22). In the multivariate analysis. Female gender and low income were found to be risk factors for high anxiety scores.
Conclusions
The 1-minute time perception assessment could not be shown to be effective in predicting depression and anxiety scores. In our study, in which the group with high depression/anxiety scores was low, the small sample size may be the reason for the insignificant result. Testing the efficacy of 1 minute time perception in larger groups can provide important data to the literature.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1999P - IMreal Cohort 4: Third interim analysis of efficacy and safety in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) receiving atezolizumab plus carboplatin and etoposide (atezo + CE) as first-line (1L) therapy under real-world conditions (RWCs)
Presenter: Sanjay Popat
Session: Poster session 05
2000P - Efficacy and safety of thoracic radiotherapy after first-line immunotherapy in extensive stage small cell lung cancer: A multi-center retrospective study
Presenter: Jiake Wu
Session: Poster session 05
2001P - Consolidative thoracic radiotherapy of extensive-stage small cell lung cancer in the era of chemoimmunotherapy: A retrospective analysis concerning patients from southern Italy
Presenter: Vito Longo
Session: Poster session 05
2002P - A multicentre study assessing the real-world effectiveness of first-line chemotherapy plus immunotherapy in extensive-stage small cell lung cancer (ES-SCLC) patients
Presenter: Marie Porte
Session: Poster session 05
2003P - Consolidative intrathoracic radiotherapy during maintenance first-line immunotherapy in extensive stage small cell lung cancer (ES-SCLC): A retrospective multicenter analysis of safety and efficacy
Presenter: Alessio Bruni
Session: Poster session 05
2004P - PD-L1 Inhibitors combined with whole brain radiotherapy in patients with small cell lung cancer brain metastases: Real-world evidence
Presenter: Litang Huang
Session: Poster session 05
2005P - Anlotinib combined with chemotherapy in the treatment of first-line extensive-stage small cell lung cancer (ES-SCLC): A real-world study
Presenter: Fangfang Gao
Session: Poster session 05
2006P - Immune activation effect and survival of different irradiated sites in ES-SCLC patients treated with radioimmunotherapy: A real-world analysis
Presenter: Min Wu
Session: Poster session 05
2007P - Real-world (rw) outcomes to chemoimmunotherapy and biomarker analysis in extensive-stage small cell lung cancer (ES SCLC)
Presenter: Emmanouil Panagiotou
Session: Poster session 05